Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
PIP's Cash to Debt is ranked higher than
96% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. PIP: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PIP' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 5.63 Max: No Debt
Current: No Debt
Equity to Asset 0.83
PIP's Equity to Asset is ranked higher than
72% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. PIP: 0.83 )
Ranked among companies with meaningful Equity to Asset only.
PIP' s Equity to Asset Range Over the Past 10 Years
Min: -0.53  Med: 0.56 Max: 0.85
Current: 0.83
-0.53
0.85
F-Score: 4
Z-Score: 13.49
M-Score: -4.82
WACC vs ROIC
15.95%
-380.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -127.06
PIP's Operating margin (%) is ranked lower than
56% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. PIP: -127.06 )
Ranked among companies with meaningful Operating margin (%) only.
PIP' s Operating margin (%) Range Over the Past 10 Years
Min: -112.69  Med: -77.40 Max: 65.1
Current: -127.06
-112.69
65.1
Net-margin (%) -133.89
PIP's Net-margin (%) is ranked lower than
57% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. PIP: -133.89 )
Ranked among companies with meaningful Net-margin (%) only.
PIP' s Net-margin (%) Range Over the Past 10 Years
Min: -166  Med: -79.10 Max: 54.98
Current: -133.89
-166
54.98
ROE (%) -34.71
PIP's ROE (%) is ranked lower than
53% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. PIP: -34.71 )
Ranked among companies with meaningful ROE (%) only.
PIP' s ROE (%) Range Over the Past 10 Years
Min: -453.67  Med: -76.43 Max: 3.93
Current: -34.71
-453.67
3.93
ROA (%) -28.50
PIP's ROA (%) is ranked lower than
51% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. PIP: -28.50 )
Ranked among companies with meaningful ROA (%) only.
PIP' s ROA (%) Range Over the Past 10 Years
Min: -111.46  Med: -42.15 Max: 2.39
Current: -28.5
-111.46
2.39
ROC (Joel Greenblatt) (%) -678.88
PIP's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. PIP: -678.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PIP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2862.64  Med: -253.60 Max: 3.27
Current: -678.88
-2862.64
3.27
Revenue Growth (3Y)(%) -31.70
PIP's Revenue Growth (3Y)(%) is ranked lower than
78% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. PIP: -31.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PIP' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -31.7  Med: -22.35 Max: 173.6
Current: -31.7
-31.7
173.6
EBITDA Growth (3Y)(%) -15.30
PIP's EBITDA Growth (3Y)(%) is ranked lower than
64% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. PIP: -15.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PIP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -54.8  Med: -28.70 Max: -9.7
Current: -15.3
-54.8
-9.7
EPS Growth (3Y)(%) -19.10
PIP's EPS Growth (3Y)(%) is ranked lower than
66% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. PIP: -19.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PIP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -63.1  Med: -29.65 Max: 29.3
Current: -19.1
-63.1
29.3
» PIP's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2014

PIP Guru Trades in Q2 2014

Jim Simons Sold Out
» More
Q3 2014

PIP Guru Trades in Q3 2014

Louis Moore Bacon 50,000 sh (New)
» More
Q4 2014

PIP Guru Trades in Q4 2014

Louis Moore Bacon 50,000 sh (unchged)
» More
Q1 2015

PIP Guru Trades in Q1 2015

Louis Moore Bacon Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PIP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NYSE:EVGN, NAS:CYTR, OTCPK:RNUGF, NAS:AKTX, OTCPK:VRACY, NAS:DMTX, AMEX:SYN, NAS:ZFGN, NAS:AVXL, OTCPK:MDGEF, OTCPK:RCAR, NAS:ATHX, OTCPK:MXDHF, NAS:IMDZ, NAS:CDXS, OTCPK:CTIX, NAS:ARGS, NAS:CDTX, AMEX:AMPE, NAS:NYMX » details
PharmAthene Inc is a biodefense company. It is engaged in the development and commercialization of medical countermeasures against biological and chemical weapons in the United States.

PharmAthene Inc was incorporated under the laws of the State of Delaware on April 25, 2005. It is a biodefense company, which is engaged in the development and commercialization of medical countermeasures against biological and chemical weapons. Its biodefense portfolio includes the product candidates namely SparVax, a second generation recombinant protective antigen (rPA) anthrax vaccine; Valortim, a fully human monoclonal antibody for the prevention and treatment of anthrax infection, and; rBChE (recombinant butyrylcholinesterase) bioscavanger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides. The Company's customers are the U.S. Department of Defense (the DoD), the National Institute of Allergy and Infectious Diseases ('NIAID), and the National Institute of Health (NIH). Its competitors include Emergent BioSolutions, Inc., Green Cross, Panacea Biotec Ltd., and PaxVax, among others. The Company is subject to various federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its various activities.

Ratios

vs
industry
vs
history
P/B 10.00
PIP's P/B is ranked lower than
84% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. PIP: 10.00 )
Ranked among companies with meaningful P/B only.
PIP' s P/B Range Over the Past 10 Years
Min: 1.3  Med: 5.75 Max: 31.07
Current: 10
1.3
31.07
P/S 33.19
PIP's P/S is ranked lower than
74% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. PIP: 33.19 )
Ranked among companies with meaningful P/S only.
PIP' s P/S Range Over the Past 10 Years
Min: 0.41  Med: 3.40 Max: 82.18
Current: 33.19
0.41
82.18
Current Ratio 6.11
PIP's Current Ratio is ranked higher than
60% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. PIP: 6.11 )
Ranked among companies with meaningful Current Ratio only.
PIP' s Current Ratio Range Over the Past 10 Years
Min: 0.41  Med: 3.83 Max: 389.51
Current: 6.11
0.41
389.51
Quick Ratio 6.11
PIP's Quick Ratio is ranked higher than
61% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. PIP: 6.11 )
Ranked among companies with meaningful Quick Ratio only.
PIP' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 3.83 Max: 389.51
Current: 6.11
0.41
389.51
Days Sales Outstanding 13.55
PIP's Days Sales Outstanding is ranked higher than
85% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. PIP: 13.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
PIP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.98  Med: 54.35 Max: 287.58
Current: 13.55
3.98
287.58

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.06
PIP's Price/Net Cash is ranked lower than
77% of the 504 Companies
in the Global Biotechnology industry.

( Industry Median: 5.38 vs. PIP: 14.06 )
Ranked among companies with meaningful Price/Net Cash only.
PIP' s Price/Net Cash Range Over the Past 10 Years
Min: 3.26  Med: 14.43 Max: 186
Current: 14.06
3.26
186
Price/Net Current Asset Value 11.95
PIP's Price/Net Current Asset Value is ranked lower than
74% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 5.07 vs. PIP: 11.95 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PIP' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.48  Med: 7.50 Max: 73.33
Current: 11.95
1.48
73.33
Price/Tangible Book 11.77
PIP's Price/Tangible Book is ranked lower than
81% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. PIP: 11.77 )
Ranked among companies with meaningful Price/Tangible Book only.
PIP' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.48  Med: 6.48 Max: 35.7
Current: 11.77
1.48
35.7
Price/Median PS Value 9.96
PIP's Price/Median PS Value is ranked lower than
97% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. PIP: 9.96 )
Ranked among companies with meaningful Price/Median PS Value only.
PIP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.2  Med: 0.98 Max: 24.12
Current: 9.96
0.2
24.12
Earnings Yield (Greenblatt) (%) -4.10
PIP's Earnings Yield (Greenblatt) (%) is ranked higher than
61% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. PIP: -4.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PIP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.7  Med: 0.80 Max: 2239
Current: -4.1
0.7
2239

More Statistics

Revenue (TTM) (Mil) $4.58
EPS (TTM) $ -0.10
Beta1.90
Short Percentage of Float2.60%
52-Week Range $1.20 - 2.49
Shares Outstanding (Mil)65.59
» More Articles for PIP

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BWEN, ENZ, PIP, HAFC, AACC Nov 21 2011 
PharmAthene Inc (PIP) CEO Eric I Richman buys 10,000 Shares Jun 21 2010 
Guru Activities for Today’s Price % Losers: PharmAthene Inc. , Authentidate Holding Corp., Kroger Dec 08 2009 

More From Other Websites
PharmAthene to Join Russell 3000® and Global Indexes Jun 23 2016
PharmAthene to Join Russell 3000® and Global Indexes Jun 23 2016
PHARMATHENE, INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jun 07 2016
ETF’s with exposure to PharmAthene, Inc. : May 27, 2016 May 26 2016
PharmAthene, Inc. :PIP-US: Earnings Analysis: Q1, 2016 By the Numbers : May 24, 2016 May 24 2016
PHARMATHENE, INC Financials May 17 2016
PHARMATHENE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 09 2016
PharmAthene Reports First Quarter 2016 Financial and Operational Results May 09 2016
PharmAthene Reports First Quarter 2016 Financial and Operational Results May 09 2016
PharmAthene Reports Court Approval of SIGA Reorganization Plan to Exit from Bankruptcy Apr 13 2016
PharmAthene Reports Court Approval of SIGA Reorganization Plan to Exit from Bankruptcy Apr 13 2016
ETF’s with exposure to PharmAthene, Inc. : April 4, 2016 Apr 04 2016
ETF’s with exposure to PharmAthene, Inc. : April 4, 2016 Apr 04 2016
ETF’s with exposure to PharmAthene, Inc. : March 23, 2016 Mar 23 2016
PharmAthene, Inc. :PIP-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 23 2016
PharmAthene, Inc. :PIP-US: Earnings Analysis: 2015 By the Numbers Mar 22 2016
PHARMATHENE, INC Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial... Mar 11 2016
/C O R R E C T I O N -- PharmAthene, Inc./ Mar 11 2016
PHARMATHENE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 11 2016
PHARMATHENE, INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)